Drug Profile
AS 0141
Alternative Names: AS-0141; AS-141; PNT-141; SRA-141Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator CrystalGenomics; SBI Biotech
- Developer Carna Biosciences; Sierra Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action CDC7 protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Suspended Cancer
Most Recent Events
- 01 Sep 2021 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Recurrent) in Japan (PO) (Carna Biosciences pipeline, September 2021)
- 11 Jun 2021 AS 0141 is available for licensing as of 11 Jun 2021. https://www.carnabio.com/
- 01 Jun 2021 Preclinical trials in Cancer is ongoing in Japan (PO) (Carna Biosciences pipeline, June 2021)